Am Fam Physician. 2006 May 15;73(10):1707-1708.
Screening for colon cancer affords family physicians an opportunity to affect the health of their patients. High-quality evidence has proved that screening saves lives,1,2 and colon cancer screening falls well within accepted cost-effectiveness parameters.3 Furthermore, a menu of screening options enables nearly every person to find an affordable, acceptable test.4,5 Public health efforts are increasing awareness of the benefits of screening,6 yet screening rates remain frustratingly low.7 Moreover, many physicians use a “screening test” that is not included in any guideline: a fecal occult blood test (FOBT) obtained at the time of a digital rectal examination (DRE).8
Physicians cite compelling arguments to justify the use of FOBT at the time of DRE. The central argument is that the patient in the office constitutes a captive audience. Performing the FOBT while the patient is in the office guarantees a 100 percent return rate. Some physicians have been able to generate a reimbursable charge for FOBT, even though the office test does not meet Medicare criteria. Furthermore, definitive evidence demonstrating the inadequacy of the DRE approach has been lacking until recently.
A study by Collins and colleagues9 in the Veteran's Affairs Cooperative Study Group should put an end to performing FOBT with DRE. They studied 2,665 persons between 50 and 75 years of age who were at average risk of colon cancer. Each person underwent three examinations: FOBT performed at home on three spontaneously passed stool specimens with the Hemoccult II test; FOBT following DRE in the physician's office; and colonoscopy, which was used to establish the sensitivity, specificity, and predictive value of the two FOBT procedures. This was the first prospective study specifically designed to assess the performance characteristics of the two approaches to FOBT, and the results were definitive. Home FOBT results were positive in 23.9 percent of persons who were found to have an adenomatous polyp of at least 1 cm, a villous adenoma, a dysplastic polyp, or cancer. FOBT obtained by DRE yielded positive results in only 4.9 percent of these patients. A negative FOBT result on DRE offered virtually no reassurance; patients with negative results on office testing had essentially the same likelihood of having advanced neoplasia as persons who underwent no stool testing at all.
Although the question of the reliability of DRE needed to be answered, the outcome does not make screening any easier. At-home FOBT is far from a perfect test. The 23.9 percent sensitivity of the six-window test is relatively low and reinforces the importance of repeating the test annually. Of concern, 12 of 21 patients with cancer tested negative on at-home FOBT. The other screening options have other obstacles to successful widespread completion.10 Fecal immunochemical testing is likely to gradually replace guaiac-based testing as the preferred technology for stool testing. The performance characteristics of this test, including the patient return rate, are superior to guaiac-based strategies.5
If you are relying on DRE to screen for colon cancer, you must stop. Instead, recommend one or more of the screening tests listed in virtually every guideline. Giving your patients the opportunity to choose from a menu of screening options increases the likelihood that each patient will find a test that he or she will adhere to. As for all aspects of preventive care, developing office systems that involve the entire office staff and that use paper or electronic prompts and tracking devices significantly increases the probability of reaching all of your eligible patients.
When age-eligible patients are seeing you for reasons other than colorectal cancer screening, take the opportunity to recommend one of the proven screening options. Scheduling specific preventive care visits is a particularly effective strategy to increase screening rates.11 No matter which approach is used—opportunistic screening or screening at a preventive visit—make sure that you follow one of several recommended screening guidelines: at-home FOBT every year, flexible sigmoidoscopy every five years (with or without annual FOBT), double-contrast barium enema every five years, or colonoscopy every 10 years.
DRE may be an easy way out, but the reassurance it offers you and your patients is false. Screen for colorectal cancer the right way: skip DRE and use tests that are proven to work.
RICHARD C. WENDER, M.D., is chairman of the Department of Family and Community Medicine at Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pa.
Address correspondence to Richard C. Wender, M.D., 1015 Walnut St., Suite 401, Philadelphia, PA 19107 (e-mail: firstname.lastname@example.org). Reprints are not available from the author.
1. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood [Published correction appears in N Engl J Med 1993;329:672]. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.
2. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–7.
3. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954–61.
4. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale [Published corrections appear in Gastroenterology 1997;112:1060 and Gastroenterology 1998;114:625]. Gastroenterology. 1997;112:594–642.
5. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al; ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001—testing for early lung cancer detection [published correction appears in CA Cancer J Clin 2001;51:150]. CA Cancer J Clin 2001; 51:38–75.
6. National Women's Health Resource Center. Dare to be aware media kit. Accessed online April 19, 2006, at: http://www.healthywomen.org/presskit/crc/main.html.
7. Centers for Disease Control and Prevention. Colorectal cancer: the importance of prevention and early detection. Accessed online April 19, 2006, at: http://www.cdc.gov/colorectalcancer/pdf/about2004.pdf.
8. Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, et al. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med. 2005;142:86–94.
9. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–5.
10. Wender RC. Barriers to screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:145–70.
11. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53:44–55.
Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions